Opinion|Videos|December 4, 2023

The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

Author(s)Misako Nagasaka, MD, PhD, Sai-Hong Ou, MD, PhD, Janellen Smith, MD

Dr Sai-Hong Ou discusses the future of treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations, highlighting the complexity of these mutations and the need for precision treatments.

Episodes in this series

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 1 Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 2 Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 3 Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 4 Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 5 Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 6 Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 7 Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

EP. 13 Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.

September 28th, 2026

First-in-Human: Jyoti Malhotra, MD, MPH on Phase I Trials, Lung Cancer in 2026, and Yale

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.

Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.

September 28th, 2026

The Value of Testing in The Expanding EGFR Exon 20 Insertion Landscape

Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.

Nursing Strategies for the 3 First-Line Regimens in EGFR-Mutated NSCLC: © Sebastian Kaulitzki - stock.adobe.com

September 25th, 2026

Nursing Strategies for the 3 First-Line Regimens in EGFR-Mutated NSCLC

Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.

Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.

September 25th, 2026

Switching to SC Dosing and Considering PRO Data for Amivantamab in NSCLC

Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.

Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.

September 24th, 2026

SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit

Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.

David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.

September 24th, 2026

How KRAS G12C Data Should Shape Combination Trial Design

David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.

September 23rd, 2026

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC

David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.

Trending on CancerNetwork

Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma

Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation

Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy

Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM

How Oncologists Can Navigate Patient Requests for Medical Aid in Dying